Bone Biologics Corporation (BBLG)
NASDAQ: BBLG · IEX Real-Time Price · USD
2.130
+0.060 (2.90%)
At close: Mar 28, 2024, 3:49 PM
2.250
+0.120 (5.63%)
After-hours: Mar 28, 2024, 7:57 PM EDT
Bone Biologics Stock Forecast
BBLG's stock price has decreased by -96.11% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Bone Biologics stock has a target of 540, which predicts an increase of 25,252.11% from the current stock price of 2.13.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 13, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for Bone Biologics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 |
---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
EF Hutton | EF Hutton | Strong Buy Reiterates $540 | Strong Buy | Reiterates | $540 | +25,252.11% | Apr 13, 2023 |
EF Hutton | EF Hutton | Strong Buy Reiterates $540 | Strong Buy | Reiterates | $540 | +25,252.11% | Apr 3, 2023 |
EF Hutton | EF Hutton | Strong Buy Initiates $540 | Strong Buy | Initiates | $540 | +25,252.11% | Oct 18, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-30.73
from -34.01
EPS Next Year
-32.19
from -30.73
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | n/a | n/a |
Avg | n/a | n/a |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -31.64 | -33.14 |
Avg | -30.73 | -32.19 |
Low | -29.53 | -30.93 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.